Steven C Plaxe Selected Research

Steven C Plaxe Research Topics

16	Neoplasms (Cancer) 01/2022 - 01/2002
6	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2002
5	Carcinoma (Carcinomatosis) 01/2020 - 11/2008
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 11/2008
2	Endometrial Neoplasms (Endometrial Cancer) 01/2019 - 02/2002
2	Lung Neoplasms (Lung Cancer) 01/2018 - 12/2017
2	Obesity 09/2015 - 04/2014
2	Fatigue 08/2015 - 11/2014
1	Monoclonal Gammopathy of Undetermined Significance 01/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 09/2020
1	Crohn Disease (Crohn's Disease) 09/2020
1	Multiple Myeloma 12/2019
1	Glioblastoma (Glioblastoma Multiforme) 12/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2019
1	Kaposi Sarcoma (Kaposi's Sarcoma) 10/2019
1	Merkel Cell Carcinoma 01/2019
1	Vitiligo 12/2017
1	Kidney Neoplasms (Kidney Cancer) 12/2017
1	Melanoma (Melanoma, Malignant) 12/2017
1	Pruritus (Itching) 12/2017
1	Infections 02/2017
1	Adenocarcinoma 01/2017
1	Renal Insufficiency (Renal Failure) 09/2015
1	Hypertension (High Blood Pressure) 09/2015
1	Heart Failure 09/2015
1	Fever (Fevers) 11/2014
1	Nausea 11/2014
1	Ascites 11/2014
1	Vomiting 11/2014
1	Abdominal Pain (Pain, Abdominal) 11/2014
1	Chills 11/2014
1	Ovarian Epithelial Carcinoma 02/2014
1	Overweight 12/2013
1	Uterine Neoplasms (Uterine Cancer) 12/2013
1	Clostridium Infections 11/2013
1	Neutropenia 08/2002
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2002

4	PlatinumIBA 01/2022 - 01/2002
4	NSC 366140 (pyrazoloacridine)IBA 08/2002 - 01/2002
2	Immune Checkpoint InhibitorsIBA 07/2021 - 09/2020
2	RNA (Ribonucleic Acid)IBA 10/2020 - 01/2002
2	NivolumabIBA 09/2020 - 12/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 11/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2017 - 11/2013
1	Immunoglobulin M (IgM)IBA 01/2022
1	adavosertibIBA 01/2022
1	Sodium Glutamate (Accent)IBA 07/2021
1	Biomarkers (Surrogate Marker)IBA 10/2020
1	Pharmaceutical PreparationsIBA 09/2020
1	pembrolizumabIBA 09/2020
1	Gemcitabine FDA Link 01/2020
1	carfilzomibIBA 12/2019
1	avelumabIBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018
1	LigandsIBA 12/2017
1	Programmed Cell Death 1 ReceptorIBA 12/2017
1	ORALIT (ORS)IBA 09/2015
1	CytokinesIBA 11/2014
1	catumaxomabIBA 11/2014
1	Antineoplastic Agents (Antineoplastics)IBA 11/2013
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2013
1	Tyrosine (L-Tyrosine)FDA Link 06/2013
1	Focal Adhesion Protein-Tyrosine KinasesIBA 06/2013
1	Messenger RNA (mRNA)IBA 06/2013
1	Biological ProductsIBA 04/2008
1	DNA (Deoxyribonucleic Acid)IBA 01/2002
1	AcridinesIBA 01/2002
1	9-methoxyacridineIBA 01/2002

8	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
7	Therapeutics 01/2022 - 01/2018
3	Radiotherapy 01/2020 - 09/2015
2	Hysterectomy 01/2017 - 12/2013
1	Intravenous Infusions 09/2020
1	Adjuvant Chemotherapy 12/2019
1	Chemoradiotherapy 12/2019
1	Immunotherapy 01/2019
1	Urinary Diversion (Ileal Conduit) 01/2016
1	Brachytherapy 09/2015
1	Terminal Care (Care, Terminal) 08/2015
1	Punctures 11/2014
1	Bariatric Surgery 04/2014
1	Lymph Node Excision (Lymph Node Dissection) 02/2014
1	Duration of Therapy 11/2013
1	Combination Drug Therapy (Combination Chemotherapy) 11/2008
1	Drug Tapering 08/2002